Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

VTGN VistaGen Therapeutics

0.151
-0.011-6.79%
Close 09/26 16:00 ET
0.153
+0.002+1.32%
Post Mkt Price 09/26 19:55 ET
High
0.168
Open
0.159
Turnover
903.12K
Low
0.145
Pre Close
0.162
Volume
5.87M
Market Cap
31.25M
P/E(TTM)
Loss
52wk High
2.780
Shares
206.84M
P/E(Static)
Loss
52wk Low
0.139
Float Cap
22.00M
Bid/Ask %
-99.33%
Historical High
63.000
Shs Float
145.59M
Volume Ratio
1.29
Historical Low
0.139
Dividend TTM
--
Div Yield TTM
--
P/B
0.68
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
4.03%
Amplitude
14.20%
Avg Price
0.153
Lot Size
1
Float Cap
22.00M
Bid/Ask %
-99.33%
Historical High
63.000
Shs Float
145.59M
Volume Ratio
1.29
Historical Low
0.139
Dividend TTM
--
P/B
0.68
Dividend LFY
--
Turnover Ratio
4.03%
Amplitude
14.20%
Avg Price
0.153
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for anxiety, depression, and other central nervous system disorders. Its portfolio includes PH94B, a neuroactive nasal spray with potential to treat multiple anxiety disorders that the company is currently preparing for phase III clinical trial for social anxiety disorder, PH10, a neuroactive nasal spray that the company is planning for phase 2b development as a stand-alone treatment for major depressive disorder (MDD), and AV-101, which the company is developing for the treatment of MDD, suicidal ideation, neuropathic pain, levodopa-induced dyskinesia, and epilepsy. The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.
CEO: Mr. Shawn K. Singh, J.D.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...